Duloxetine Capsule, Delayed Release
Product Images NDC 51655-237

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 51655-237). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 237 25 Master Bottle Label Approval Rev A 04 21)

Label for Duloxetine delayed-release capsules, 60 mg strength, containing 60 capsules. The label states it is prescription only and includes storage instructions at 25°C with permitted excursions. Manufactured and repackaged by Northwind Pharmaceuticals, Indianapolis, IN.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve chart depicting the proportion of patients experiencing relapse over time (days) from randomization for Duloxetine compared to placebo. The x-axis shows time in days, and the y-axis shows the proportion of patients with relapse. The Duloxetine curve shows a lower relapse proportion than placebo.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines represent placebo and Duloxetine 60/120 mg once daily treatment groups, showing higher improvement rates for Duloxetine across pain improvement percentages.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line chart comparing the proportion of patients with relapse over time from randomization to relapse (days) between Duloxetine and placebo treatments. The y-axis shows the proportion of patients with relapse (0.0 to 1.0), and the x-axis shows time in days (0 to 300). Duloxetine shows a lower proportion of relapse compared to placebo throughout the observed period.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at different dosages (60 mg BID, 60 mg QD, 20 mg QD) compared to placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 70%. Four distinct lines represent the different treatment groups and placebo over the range of pain improvement.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg taken twice daily (BID), Duloxetine 60 mg taken once daily (QD), and placebo groups showing trends in pain improvement percentages across different levels of pain improvement.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph showing the percentage of patients improved relative to the percent improvement in pain from baseline. It compares Duloxetine 60 mg administered twice daily, Duloxetine 60 mg once daily, and placebo, with the percentage of patients improved decreasing as the percent improvement in pain increases across the x-axis.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses of 120 mg, 60 mg, 20 mg once daily, and placebo. The graph compares patient improvement across different pain reduction thresholds, with Duloxetine doses showing higher improvement percentages than placebo.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved with Duloxetine 60/120 mg once daily versus placebo across different levels of percent improvement in pain from baseline (BOCF). The y-axis represents the percentage of patients improved, and the x-axis shows increasing thresholds of percent improvement in pain, from greater than 0% to 100%. The graph illustrates a higher percentage of improvement in the Duloxetine group compared to placebo at most thresholds.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved between Duloxetine 60 mg once daily and placebo groups. The x-axis shows percent improvement in pain from baseline (BOCF), ranging from >0 to 100, and the y-axis shows the percentage of patients improved, ranging 0 to 100%. The graph displays higher patient improvement percentages for Duloxetine compared to placebo across varying pain improvement thresholds.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure diagram of duloxetine hydrochloride showing its molecular framework with bicyclic and thiophene rings and hydrochloride salt form, corresponding to the active ingredient duloxetine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.